Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 52 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, March 23 by Mizuho. On Friday, September 8 the stock rating was maintained by Piper Jaffray with “Hold”. The firm has “Neutral” rating given on Tuesday, February 14 by Mizuho. On Thursday, March 10 the stock rating was initiated by Leerink Swann with “Outperform”. Piper Jaffray downgraded the stock to “Underweight” rating in Monday, December 12 report. On Friday, July 14 the stock rating was maintained by RBC Capital Markets with “Hold”. As per Tuesday, August 8, the company rating was downgraded by Janney Capital. The firm has “Hold” rating by Cantor Fitzgerald given on Tuesday, November 8. The company was maintained on Thursday, September 14 by RBC Capital Markets. The stock has “Neutral” rating by PiperJaffray on Wednesday, July 27. See Depomed, Inc. (NASDAQ:DEPO) latest ratings:
23/03/2018 Broker: Mizuho Rating: Buy New Target: $9.0000 Maintain
02/03/2018 Broker: Roth Capital Rating: Buy New Target: $10.0 Maintain
06/12/2017 Broker: RBC Capital Markets Rating: Hold New Target: $9.0 Maintain
05/12/2017 Broker: Piper Jaffray Rating: Hold New Target: $9.0 Maintain
05/12/2017 Broker: Mizuho Old Rating: Neutral New Rating: Buy Old Target: $17 Upgrade
10/11/2017 Broker: UBS Rating: Neutral Old Target: $6 Maintain
08/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $6.0 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $8.0 Maintain
Disciplined Growth Investors Inc increased Cognex Corp Com (CGNX) stake by 97.76% reported in 2017Q4 SEC filing. Disciplined Growth Investors Inc acquired 414,079 shares as Cognex Corp Com (CGNX)’s stock declined 13.83%. The Disciplined Growth Investors Inc holds 837,649 shares with $51.23 million value, up from 423,570 last quarter. Cognex Corp Com now has $8.17B valuation. The stock decreased 2.38% or $1.15 during the last trading session, reaching $47.24. About 1.79M shares traded. Cognex Corporation (NASDAQ:CGNX) has risen 31.99% since April 25, 2017 and is uptrending. It has outperformed by 20.44% the S&P500.
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $423.65 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.
Investors sentiment decreased to 0.93 in Q4 2017. Its down 0.28, from 1.21 in 2017Q3. It turned negative, as 28 investors sold Depomed, Inc. shares while 47 reduced holdings. 24 funds opened positions while 46 raised stakes. 55.87 million shares or 0.97% less from 56.42 million shares in 2017Q3 were reported. 152 were accumulated by Assetmark. Panagora Asset Mngmt invested in 0% or 11,760 shares. Parallax Volatility Advisers L P reported 0% in Depomed, Inc. (NASDAQ:DEPO). Deltec Asset Mgmt Ltd Llc reported 826,907 shares stake. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Depomed, Inc. (NASDAQ:DEPO) for 2,550 shares. Regions has 273 shares for 0% of their portfolio. Comerica Comml Bank stated it has 64,629 shares. Morgan Stanley reported 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Jane Street Group Limited Liability Corporation holds 0% or 15,835 shares. Trexquant Investment Limited Partnership holds 41,110 shares or 0.04% of its portfolio. Voya Invest Mngmt Ltd Liability Corporation reported 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). The Texas-based Teacher Retirement Systems Of Texas has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Systematic Financial Mngmt Lp reported 0.04% stake. Ls Invest Advsr Ltd Llc has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Public Sector Pension Inv Board accumulated 39,429 shares.
The stock decreased 2.34% or $0.16 during the last trading session, reaching $6.67. About 838,534 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 57.25% since April 25, 2017 and is downtrending. It has underperformed by 68.80% the S&P500.
Since December 14, 2017, it had 1 buy, and 1 sale for $312,485 activity. HIGGINS ARTHUR J had bought 75,000 shares worth $612,000. The insider Gosling Matthew M sold 45,519 shares worth $299,515.
Disciplined Growth Investors Inc decreased Ultra Petroleum Corp stake by 8.73M shares to 1.07M valued at $96.55 million in 2017Q4. It also reduced Align Technology Inc (NASDAQ:ALGN) stake by 95,751 shares and now owns 993,617 shares. Dolby Laboratories Inc Com (NYSE:DLB) was reduced too.
Since March 12, 2018, it had 0 buys, and 1 sale for $564,892 activity. Another trade for 10,000 shares valued at $564,892 was sold by SUN ANTHONY.
Among 19 analysts covering Cognex Corporation (NASDAQ:CGNX), 8 have Buy rating, 1 Sell and 10 Hold. Therefore 42% are positive. Cognex Corporation had 42 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, November 3 the stock rating was downgraded by Credit Agricole to “Outperform”. As per Friday, February 17, the company rating was maintained by Needham. The firm has “Outperform” rating by CLSA given on Monday, November 7. The firm earned “Hold” rating on Thursday, February 15 by Canaccord Genuity. The company was upgraded on Tuesday, April 3 by J.P. Morgan. JP Morgan upgraded the stock to “Neutral” rating in Tuesday, April 3 report. Robert W. Baird maintained Cognex Corporation (NASDAQ:CGNX) on Tuesday, October 31 with “Neutral” rating. The rating was downgraded by Canaccord Genuity on Tuesday, August 4 to “Hold”. The firm earned “Hold” rating on Tuesday, June 14 by Canaccord Genuity. The company was initiated on Friday, January 22 by Raymond James.